Mesa Labs profit surges as biopharma growth offsets China headwinds
Mesa Laboratories (NASDAQ:MLAB) reported a sharp increase in profitability for its third fiscal quarter, as strong demand for its biopharmaceutical tools more than offset a collapse in its Chinese diagnostic business.











